Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ALDH3A1 | P30838 | 5/20 | 0.53 |
| ▸ | BRD4 | O60885 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3998489 | 0.92 | KMT2A (0.70) | KMT2AMEN1PKMALDH1A1MAPT | |
| SCHEMBL3994749 | 0.88 | MEN1 (0.55) | KMT2AMEN1PKMALDH1A1MAPT | |
| SCHEMBL3995520 | 0.86 | MEN1 (0.53) | KMT2AMEN1PKMALDH1A1MAPT | |
| SCHEMBL3997877 | 0.83 | PKM (0.53) | KMT2AMEN1PKMALDH1A1MAPT | |
| SCHEMBL3997164 | 0.83 | ALDH1A1 (0.65) | KMT2AMEN1PKMALDH1A1MAPT | |
| SCHEMBL1956219 | 0.82 | MAPT (0.56) | KMT2AMEN1PKMALDH1A1MAPT | |
| SCHEMBL1956216 | 0.82 | MAPT (0.56) | KMT2AMEN1PKMALDH1A1MAPT | |
| SCHEMBL9604230 | 0.82 | KAT2B (0.58) | KMT2AMEN1ALDH1A1MAPTHTT | |
| SCHEMBL30150839 | 0.82 | KMT2A (0.57) | KMT2AMEN1PKMALDH1A1MAPT | |
| SCHEMBL2019323 | 0.81 | LMNA (0.72) | KMT2AMEN1PKMALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994011-B1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | RAQUALIA PHARMA INC (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-7700618-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7598393-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090137584-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | RAQUALIA PHARMA INC. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1809607-B1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | KON-I KANA | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137584-A1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | TRPV1, CNR2, CNR1 | KMT2A 4180/4885MEN1 3529/4885PKM 3625/4885 |
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | TRPV1, CNR2, CNR1 | KMT2A 4021/4885MEN1 3669/4885PKM 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.